colorectal cancer

colorectal cancer
Name	Colorectal cancer
Field	Oncology, Gastroenterology

colorectal cancer is a malignant neoplasm arising from the colon or rectum, commonly developing from adenomatous polyps through accumulated genetic and epigenetic alterations. It occupies a central place in global oncology practice, intersects with screening programs led by national health agencies, and is a focus of clinical trials at major centers such as Mayo Clinic, Memorial Sloan Kettering Cancer Center, and Johns Hopkins Hospital. Management draws on multidisciplinary teams including surgeons trained at institutions like Cleveland Clinic and oncologists affiliated with societies such as the American Society of Clinical Oncology.

Signs and symptoms

Patients commonly present with a constellation of changes including altered bowel habits, hematochezia, and abdominal discomfort; these findings prompt evaluation in primary care settings such as Kings College Hospital or outpatient clinics in networks like the National Health Service. Symptoms overlap with benign conditions evaluated at centers such as Mayo Clinic and often lead to referrals to specialists who practice at hospitals like Massachusetts General Hospital. Alarm features that accelerate investigation include iron-deficiency anemia identified in laboratories at institutions like UCLA Health and unexplained weight loss documented in records from systems such as Kaiser Permanente. Advanced disease may present with bowel obstruction managed surgically at tertiary centers like Mount Sinai Hospital or with metastatic symptoms to the liver assessed by teams at Royal Free Hospital.

Causes and risk factors

Risk derives from hereditary syndromes and environmental exposures recognized in pedigree studies from centers including St Bartholomew's Hospital and registries such as the Surveillance, Epidemiology, and End Results Program. High-penetrance inherited mutations such as mismatch repair defects seen in Lynch syndrome families and APC mutations observed in Familial adenomatous polyposis account for early-onset cases treated in specialist clinics like Great Ormond Street Hospital. Moderate risks accrue from conditions such as longstanding inflammatory bowel disease managed at clinics like Mount Sinai Hospital and metabolic states characterized by obesity tracked by public health agencies such as the Centers for Disease Control and Prevention. Dietary patterns associated with higher incidence were highlighted in cohort studies led by investigators affiliated with Harvard T.H. Chan School of Public Health and University of Oxford; additional epidemiologic risk factors include tobacco exposure examined by researchers at University College London and alcohol use studied at University of Cambridge.

Pathophysiology

Neoplastic transformation typically follows an adenoma–carcinoma sequence first elucidated in classic studies by investigators at University of Minnesota and later expanded using molecular profiling from groups at The Institute of Cancer Research. Genetic events include APC loss, KRAS activation, and TP53 inactivation analogous to paradigms developed by researchers at Cold Spring Harbor Laboratory and Sanger Institute. Microsatellite instability resulting from defective mismatch repair, characterized in families seen at Addenbrooke's Hospital, underlies an alternative pathway linked to hypermutated tumors studied at Broad Institute. Tumor microenvironment interactions involving stromal cells and immune infiltrates mirror findings reported by immunology teams at Institut Pasteur and influence responsiveness to therapies developed by companies such as Genentech and Merck & Co..

Diagnosis

Diagnostic algorithms emphasize structural and molecular tests implemented in clinical centers like Royal Marsden Hospital and laboratories certified by agencies such as Clinical Laboratory Improvement Amendments. Colonoscopy with biopsy, performed by endoscopists trained at Mayo Clinic or University College Hospital, remains the gold standard; pathology is reported according to staging systems endorsed by bodies such as the Union for International Cancer Control and American Joint Committee on Cancer. Cross-sectional imaging with CT or MRI used at radiology departments in institutions like Johns Hopkins Hospital and PET scanning available at centers such as Memorial Sloan Kettering Cancer Center define extent. Molecular profiling including mismatch repair testing and next-generation sequencing provided by laboratories at Sanger Institute and Broad Institute guides targeted therapies and enrollment in trials run by networks like European Organisation for Research and Treatment of Cancer.

Prevention and screening

Population screening programs administered by public health systems such as the National Health Service and agencies like the Centers for Disease Control and Prevention reduce mortality by detecting premalignant lesions; modalities include fecal immunochemical testing promoted by organizations like World Health Organization and direct visualization through colonoscopy provided by hospitals such as Royal Devon and Exeter Hospital. Chemoprevention trials evaluating aspirin and other agents have been coordinated by research groups at University of Oxford and University of Edinburgh. High-risk individuals from families with Lynch syndrome or Familial adenomatous polyposis follow intensified surveillance protocols developed at specialty clinics including National Institutes of Health clinical research units.

Treatment

Management is multimodal and delivered at tertiary centers such as Memorial Sloan Kettering Cancer Center, Royal Marsden Hospital, and Mayo Clinic by teams combining surgical oncology, medical oncology, and radiation oncology. Curative resection performed by colorectal surgeons trained at Cleveland Clinic often follows staging algorithms from the American Society of Clinical Oncology; adjuvant chemotherapy regimens derive from trials conducted by cooperative groups like North Central Cancer Treatment Group and European Organisation for Research and Treatment of Cancer. Metastatic disease may be managed with systemic targeted agents developed by pharmaceutical companies such as Roche and Pfizer, immunotherapy agents from Merck & Co. in selected mismatch repair–deficient tumors, and hepatic metastasectomy or ablation performed at specialist centers like Royal Infirmary of Edinburgh. Palliative care services coordinated with hospices such as St Christopher's Hospice support symptom control.

Epidemiology and prognosis

Incidence and mortality statistics are tracked by organizations including the World Health Organization and the International Agency for Research on Cancer; burden varies geographically with high rates reported in countries monitored by the Global Burden of Disease Study. Prognosis depends on stage at diagnosis using staging from the American Joint Committee on Cancer and outcome data from registries like the Surveillance, Epidemiology, and End Results Program; five-year survival ranges widely and has improved with advances reported by clinical trial networks such as National Surgical Adjuvant Breast and Bowel Project and treatment centers including Memorial Sloan Kettering Cancer Center. Public health initiatives led by agencies such as the European Centre for Disease Prevention and Control aim to reduce disparities in outcomes across populations.

Category:Cancer